Camille L. Bedrosian - 30 Jan 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP and Chief Medical Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
30 Jan 2022
Net transactions value
-$109,859
Form type
4
Filing time
01 Feb 2022, 12:39:50 UTC
Previous filing
18 Oct 2021
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $109,859 -1,657 -4.3% $66.30 36,759 30 Jan 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.